|Generic name||Brentuximab vedotin|
|Brand name(s), other common name(s)||AdcetrisTM|
|Drug type||Antibody conjugate|
|How the drug is given||Intravenously (IV)|
Brentuximab vedotin is FDA approved for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for ASCT. It is also approved for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
Side effects needing medical attention:Peripheral neuropathy; infusion reactions; low white cell counts; fatigue; nausea; anemia; upper respiratory tract infection; diarrhea; fever; rash; low platelet counts; cough; vomiting.
Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with brentuximab vedotin.
The FDA warns against use of brentuximab vedotin with the cancer drug bleomycin due to increased risk of pulmonary toxicity.